ArticleThoracic cancer2018
hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- circ_0046599 Promotes HCC Progression by Competing with miR-1322 to Enhance NT5DC2 Expression.Journal of Cancer · 2025Article
- Development of a Novel Prognostic Model for Lung Adenocarcinoma Utilizing Pyroptosis-Associated LncRNAs.Analytical cellular pathology (Amsterdam) · 2025Article
- Construction of circRNA-miRNA-mRNA ceRNA regulatory network and screening of diagnostic targets for tuberculosis.Annals of medicine · 2024Article
- Article
- circGRAMD1B contributes to migration, invasion and epithelial-mesenchymal transition of lung adenocarcinoma cells via modulating the expression of SOX4.Functional & integrative genomics · 2023Article
- Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection.International journal of molecular sciences · 2023Article
- Hsa_circ_0070661 inhibits cancer progression through miR-556-5p/TEK axis in lung adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.Oncology letters · 2022Review
- Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.Molecular oncology · 2022Article
- Circular RNA (circ)_0129047 upregulates bone morphogenetic protein receptor type 2 expression to inhibit lung adenocarcinoma progression by sponging microRNA (miR)-1206.Bioengineered · 2022Article
- Effect Of XBP1 Deficiency In Cartilage On The Regulatory Network Of LncRNA/circRNA-miRNA-mRNA.International journal of biological sciences · 2022Article
- Hsa_circ_0003288 facilitates tumor progression by targeting miR-145 in non-small cell lung cancer cells.Cancer biomarkers : section A of Disease markers · 2022Article
- CircRNA6783 Inhibits Cell Proliferation and Promotes Apoptosis in Lung Adenocarcinoma.Cancer management and research · 2022Article
- Systematic screen of potential circular RNA biomarkers of Hirschsprung's disease.Translational pediatrics · 2022Article
- Circular RNA-Is the Circle Perfect?Biomolecules · 2021Review
- Circular RNA hsa_circ_0002483 promotes growth and invasion of lung adenocarcinoma by sponging miR-125a-3p.Cancer cell international · 2021Article
- circRNA hsa_circ_0018414 inhibits the progression of LUAD by sponging miR-6807-3p and upregulating DKK1.Molecular therapy. Nucleic acids · 2021Article
- Cancer-related circular RNA: diverse biological functions.Cancer cell international · 2021Review
- Knockdown of hsa_circ_0000729 Inhibits the Tumorigenesis of Non-Small Cell Lung Cancer Through Mediation of miR-1281/FOXO3 Axis.Cancer management and research · 2021Article
- Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for cancer progression.
methodsWe examined differentially expressed circRNAs in LUAD and paired normal tissues using downloaded circRNA microarrays from the Gene Expression Omnibus. We constructed gene co-expression networks based on the degree of Pearson correlation to predict the critical circRNA in LUAD. Gene Ontology analysis was performed on the genes in the network. We observed one novel circRNA upregulated in LUAD, hsa_circ_0000792, as well as its potential sponged microRNA, miR-375. Subsequent real-time quantitative PCR was used to verify the bioinformatics analysis.
resultsSeveral circRNAs showed significantly different expression levels in LUAD tissues. Real-time quantitative PCR and further co-expression network analysis of 42 matched tissue samples showed a significant difference in expression between LUAD and normal tissues in hsa_circ_0000792 (P < 0.001). We built a network of hsa_circ_0000792-targeted miRNA gene interactions, including miR-375 and the corresponding messenger RNAs. Gene Ontology analysis revealed that hsa_circ_0000792 could participate in signal transduction and cell communication during LUAD development. Larger area under the curve by receiver operating characteristic curve analysis of hsa_circ_0000792 and miR-375 (0.815 and 0.772, respectively) in LUAD indicated greater potential as biomarkers.
conclusionsWe identified hsa_circ_0000792 as a potential LUAD biomarker; however, further studies are required to determine the mechanism of this circRNA in LUAD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.